What is HC Wainwright’s Estimate for DMRA Q2 Earnings?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for Damora Therapeutics, Inc. Common Stock in a research report issued to clients and investors on Thursday, June 11th. HC Wainwright analyst M. Kapoor expects that the company will earn ($0.32) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.51) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.53) EPS.

DMRA has been the topic of a number of other reports. TD Cowen began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating on the stock. UBS Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price for the company. Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Finally, Wedbush reiterated an “outperform” rating and set a $35.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA stock opened at $20.78 on Monday. The firm has a fifty day simple moving average of $24.50 and a two-hundred day simple moving average of $25.40. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The firm has a market capitalization of $1.28 billion, a PE ratio of -3.72 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23).

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $6,574,000. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $40,000. Boothbay Fund Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $2,204,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,774,000. Finally, Remedium Capital Partners LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,772,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Damora Therapeutics, Inc. Common Stock

Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:

• Positive Sentiment: Wedbush started coverage on Damora Therapeutics with an Outperform rating, adding another bullish analyst view for the stock. Damora Therapeutics Receives Outperform Rating from Wedbush
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $45 price target, suggesting analysts believe DMRA remains undervalued relative to its long-term potential.
• Neutral Sentiment: HC Wainwright’s updated forecasts call for continued per-share losses in 2026 and 2027, with estimated EPS ranging from about $(0.32) to $(0.35) per quarter and full-year losses of $(1.51) in FY2026 and $(1.53) in FY2027.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.